NCT06609304View on ClinicalTrials.gov

Axicabtagene Ciloleucel for Consolidation After First-line Treatment of High-risk Large B-cell Lymphoma

PHASE4RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

September 30, 2024

Primary Completion Date

August 31, 2026

Study Completion Date

August 31, 2027

Conditions
Lymphoma, B-Cell
Interventions
BIOLOGICAL

Axicabtagene Ciloleucel

Axicabtagene Ciloleucel at 2.0×10\^6/Kg

Trial Locations (1)

450052

RECRUITING

The First Affiliated Hospital of Zhengzhou University, Department of Oncology, Zhengzhou

All Listed Sponsors
lead

Zhengzhou University

OTHER